Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPS Regimen in R/R Primary CNS Diffuse Large B-Cell Lymphoma
NCT07523737Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide, tislelizumab, selinexor in primary central nervous system lymphoma (PCNSL), diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Tongren Hospital. Started Apr 2026; status: recruiting.
02
Drugs
pomalidomidetislelizumabselinexor
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07523737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523737.